Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03265314 · ClinicalTrials.gov registry record · NA
LeadHer, a Gender-specific Teen Pregnancy Prevention Curriculum for Girls 15-19
A NA study, sponsored by Alternatives For Girls.
- Completed
- Registry status
- NA
- Development phase
- 508
- Enrollment target
NCT03265314: Completed NA study, sponsored by Alternatives For Girls.
NCT03265314 is a NA study that has completed, run by Alternatives For Girls. The registered enrollment target is 508 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03265314, a NA study, has completed, sponsored by Alternatives For Girls.
- COMPLETED
- Registry status
- NA
- Development phase
- 508 participants
- Enrollment target
Study Summary
Alternatives For Girls (AFG) is offering LeadHer as a gender-specific teen pregnancy prevention curriculum to girls between the ages of 14-19 years old who live in Wayne County, MI. The curriculum seeks to demonstrate that girls who participate in LeadHer will show increased rates of avoidance of unprotected sex, will show increased use of birth control and reduced rates of pregnancy. LeadHer will run over a 6-session period covering topics designed to prevent teen pregnancy and develop girls into leaders. The sessions will be co-led by youth (Peer Educators).
Primary Outcome
Participants will refrain from having sex or avoid sex without protection.
Interventions
- BEHAVIORAL LeadHer
- BEHAVIORAL Sassy Science
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 508 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2022-04-30 |
| Phase | NA |
What the finished NCT03265314 record still lists
NCT03265314 is an interventional study that assigns participants to a tested intervention. The registered 508 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 2 interventions - of which LeadHer is the first listed.
NCT03265314 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03265314 about?
NCT03265314 is a clinical study titled "LeadHer, a Gender-specific Teen Pregnancy Prevention Curriculum for Girls 15-19". Alternatives For Girls (AFG) is offering LeadHer as a gender-specific teen pregnancy prevention curriculum to girls between the ages of 14-19 years old who live in Wayne County, MI. The curriculum seeks to demonstrate that girls who participate in LeadHer will show increased rates of avoidance of un...
What is the current status of trial NCT03265314?
This trial is currently completed. It is a NA study. The enrollment target is 508 participants. The study started on 2017-08-01. Estimated completion is 2022-04-30.
What interventions are being tested in trial NCT03265314?
The interventions under investigation include: LeadHer (BEHAVIORAL), Sassy Science (BEHAVIORAL).
Who is sponsoring clinical trial NCT03265314?
This trial is sponsored by Alternatives For Girls, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03265314's enrollment target sits among peer trials
508 192nd of 2000 higher than 1,808 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02115295 · 508 participants · Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- NCT04692675 · 508 participants · NA
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
- NCT07391657 · 508 participants · Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- NCT07484217 · 508 participants · Phase 3
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI